Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer

NCT00367601 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: Erlotinib
DRUG: Bevacizumab

Sponsor

Nasser Hanna, M.D.

Collaborators

[object Object]
[object Object]
[object Object]